Overview
- IQVIA reported second-quarter revenue of $4.37 billion and adjusted earnings per share of $3.15, results the company disclosed on Tuesday, July 28, 2026 that topped analysts' estimates.
- After the report the company raised its 2026 revenue range to about $17.28 billion–$17.48 billion and lifted adjusted EPS guidance to $12.80–$13.00 per share.
- Research & Development Solutions drove the beat, with revenue of $2.58 billion, net new bookings of $3.15 billion and a book-to-bill ratio of 1.22, a sign the company has more contracted work than it recognized this quarter.
- Investors reacted to the stronger results and bigger buyback plan by sending the stock sharply higher and the company disclosed an upsized $2.819 billion share repurchase authorization after repurchasing $398 million in Q2.
- Analysts say the lift reflects recovering biotech funding and greater outsourcing by drugmakers, which could boost demand for CRO, data and safety services and extend revenue visibility over coming quarters.